Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2273-2282

  Ireno, Ivanildce Cristiane ^a   Wiehe, Rahel Stephanie ^a   Stahl, Andreea Iulia ^a   Hampp, Stephanie ^a   Aydin, Sevtap ^a,b   A Troester, Melissa ^c   Selivanova, Galina ^d   Wiesmüller, Lisa ^a  

^a UNIVERSITY OF ULM   (Germany)

^b HACETTEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ISOQUINOLINEDIOL; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PIFITHRIN ALPHA; PROTEIN P53; UNCLASSIFIED DRUG; 1,5-DIHYDROXYISOQUINOLINE; BENZOTHIAZOLE DERIVATIVE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; PIFITHRIN; PIPERAZINE DERIVATIVE; SMALL INTERFERING RNA; TOLUENE;

ARTICLE; BREAST CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA RECOMBINATION; DNA STRAND BREAKAGE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; MOLECULAR WEIGHT; RECOMBINATION REPAIR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BENZOTHIAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENES, P53; HUMANS; IMIDAZOLES; ISOQUINOLINES; MOLECULAR WEIGHT; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINATIONAL DNA REPAIR; RNA, SMALL INTERFERING; TOLUENE;

EID: 84929045263     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu160     Document Type: Article

References (50)

1. De Vos, M. et al. (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol., 84, 137-146.
2. Helleday, T. et al. (2008) DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer, 8, 193-204.
3. Ying, S. et al. (2012) MRE11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res., 72, 2814-2821.
4. Murai, J. et al. (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res., 72, 5588-5599.
5. Do, K. et al. (2013) Molecular pathways: targeting PARP in cancer treatment. Clin. Cancer Res., 19, 977-984.
6. McCabe, N. et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res., 66, 8109-8115.
7. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
8. Bertrand, P. et al. (2004) p53's double life: transactivation-independent repression of homologous recombination. Trends Genet., 20, 235-243.
9. Sengupta, S. et al. (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol., 6, 44-55.
10. Gatz, S.A. et al. (2006) p53 in recombination and repair. Cell Death Differ., 13, 1003-1016.
11. Restle, A. et al. (2008) Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res., 36, 5362-5375.
12. Linke, S.P. et al. (2003) p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res., 63, 2596-2605.
13. Gobert, C. et al. (1999) The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc. Natl. Acad. Sci. USA, 96, 10355-10360.
14. Yang, Q. et al. (2002) The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J. Biol. Chem., 277, 31980-31987.
15. Sommers, J.A. et al. (2005) p53 modulates RPA-dependent and RPAindependent WRN helicase activity. Cancer Res., 65, 1223-1233.
16. Gudkov, A.V. et al. (2005) Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun., 331, 726-736.
17. Popowicz, G.M. et al. (2011) The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew. Chem. Int. Ed. Engl., 50, 2680-2688.
18. Keimling, M. et al. (2009) DNA double-strand break repair activities in mammary epithelial cells-influence of endogenous p53 variants. Carcinogenesis, 30, 1260-1268.
19. Troester, M.A. et al. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer, 6, 276.
20. Ahn, J. et al. (2009) Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle, 8, 1603-1615.
21. Ireno, I.C. et al. (2014) Fluorescence based recombination assay for sensitive and specific detection of genotoxic carcinogens in human cells. Arch. Toxicol., 88, 1141-1159.
22. Issaeva, N. et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med., 10, 1321-1328.
23. Böhringer, M. et al. (2013) siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/-with susceptibility versus C57BL/6-Trp53+/-mice with resistance to mammary tumors. Oncogene, 32, 5458-5470.
24. Vassilev, L.T. et al. (2004) In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science, 303, 844-848.
25. Komarov, P.G. et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285, 1733-1737.
26. Arias-Lopez, C. et al. (2006) p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep., 7, 219-224.
27. Boehden, G.S. et al. (2004) Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53. Carcinogenesis, 25, 1305-1313.
28. Schärer, E. et al. (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res., 20, 1539-1545.
29. Delia, D. et al. (1996) p53 activity and chemotherapy. Nat. Med., 2, 724-725.
30. Troester, M.A. et al. (2004) Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res., 64, 4218-4226.
31. Kranz, D. et al. (2012) A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy. Cell Cycle, 11, 2053-2054.
32. Essmann, F. et al. (2004) Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res., 64, 7065-7072.
33. Ozretic, L. et al. (2011) High nuclear poly (adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1-and BRCA2-deficient breast cancer. J. Clin. Oncol., 29, 4586-4588.
34. Yehiely, F. et al. (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol. Med., 12, 537-544.
35. Damia, G. et al. (2007) Targeting DNA repair as a promising approach in cancer therapy. Eur. J. Cancer, 43, 1791-1801.
36. Grinkevich, V.V. et al. (2009) Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell, 15, 441-453.
37. Poyurovsky, M.V. et al. (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat. Struct. Mol. Biol., 17, 982-989.
38. Sohn, D. et al. (2009) Pifithrin-alpha protects against DNA damageinduced apoptosis downstream of mitochondria independent of p53. Cell Death Differ., 16, 869-878.
39. Gaiddon, C. et al. (1999) Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J., 18, 5609-5621.
40. Offer, H. et al. (2001) Structural and functional involvement of p53 in BER in vitro and in vivo. Oncogene, 20, 581-589.
41. Zhou, J. et al. (2001) A role for p53 in base excision repair. EMBO J., 20, 914-923.
42. Prives, C. et al. (1999) The p53 pathway. J. Pathol., 187, 112-126.
43. Gudkov, A.V. et al. (2002) Converting p53 from a killer into a healer. Nat. Med., 8, 1196-1198.
44. Milyavsky, M. et al. (2010) A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell, 7, 186-197.
45. Elstrodt, F. et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res., 66, 41-45.
46. Ma, W. et al. (2012) Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. Oncogene, 31, 1024-1033.
47. Oplustilova, L. et al. (2012) Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle, 11, 3837-3850.
48. Fong, P.C. et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol., 28, 2512-2519.
49. Mukhopadhyay, A. et al. (2012) Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res., 72, 5675-5682.
50. Martinez-Rivera, M. et al. (2012) Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem. Pharmacol., 83, 1049-1062.